Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Corporate Profile for Ligand Pharmaceuticals Incorporated, dated Friday, Feb. 8, 2002.


Business Editors

--(BUSINESS WIRE)

The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-


Published Date:   Feb. 8, 2002

Company Name:     Ligand Pharmaceuticals Incorporated

Address:          10275 Science Center Drive
                  San Diego, CA 92121

Main Telephone
 Number:          858/550-7500

Internet Home
 Page Address
  (URL)           www.ligand.com

Chief Executive
 Officer:         David E. Robinson

Chief Financial
 Officer:         Paul V. Maier

Investor Relations
 Contact:         Michael J. Watts
 Business number: 858/550-7850
 E-mail address:  investors@ligand.com

Industry:         Biotechnology/Pharmaceuticals

Trading Symbol/
 Exchange:        Nasdaq:LGND

Market Makers:    Bear Stearns, CSFB, Dain Rauscher, JP Morgan, Legg
                  Mason, Lehman, Merrill Lynch, Morgan Stanley, Spear,
                  Leeds & Kellogg.


Company description: Ligand ligand (lĭg`ənd), charged or uncharged molecule with one or more unshared pairs of electrons that can attach to a central metallic atom or ion to form an aggregate known as a complex ion (see chemical bond).  Pharmaceuticals Incorporated (Nasdaq:LGND LGND Luminance Ground ) discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men's and women's hormone-related diseases as well as osteoporosis, metabolic disorders Noun 1. metabolic disorder - a disorder or defect of metabolism
disorder, upset - a physical condition in which there is a disturbance of normal functioning; "the doctor prescribed some medicine for the disorder"; "everyone gets stomach upsets from time to time"
 and cardiovascular and inflammatory diseases. Ligand has four drugs approved for marketing in the U.S. -- Targretin(R) capsules, Targretin(R) gel, ONTAK(R), and Panretin(R) gel -- that are being marketed through its specialty oncology and dermatology dermatology (dûrmətŏl`əjē), branch of medicine concerned with diagnosis and treatment of diseases and disorders of the skin.  sales force. Morphelan(TM), a pain relief product licensed from Elan (Emulated LAN) A virtual LAN in the ATM world. See LANE and virtual LAN.

Elan - ["Top-down Programming with Elan", C.H.A. Koster, Ellis Horwood 1987].
, is currently under FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 review.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 8, 2002
Words:224
Previous Article:Galaxy and Venetian Granted a Provisional Concession for Macau Gaming License.
Next Article:Boeing Delta II Launch of Iridium Satellites Scrubbed.
Topics:



Related Articles
Ligand and Ferrer Enter Into Marketing and Distribution Agreements for ONTAK, Targretin and Panretin.
Corporate Profile for Ligand Pharmaceuticals Incorporated, dated May 7, 1999.
Corporate Profile for Ligand Pharmaceuticals Incorporated, dated Fri. Jan. 28, 2000.
Ligand Presents Data on Novel RXR Homodimer Antagonist Compound with Potential Utility in Diabetes and Obesity.
Ligand Completes $10 Million Takedown of Elan Funding.
Ligand Raises $24 Million in Private Placement of Common Stock.
Ligand Agrees On Early Conversion of $50 Million in Elan Notes; One-Time Charge of $5.0 Million Will Eliminate Related Future Non-Operating Expenses.
Ligand Presentation at Lehman Health Care Conference Will Be Available Via Conference Call.
Ligand, Elan Agree On Early Conversion of $20 Million Note, Early Exercise of Ligand Warrants.
Ligand Raises $69.3 Million in Private Placement of Common Stock.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles